Effects of new multi-site hormone blockers on the fertility of male rats.
The effects on the fertility of adult male rats of six new synthetic steroids: I, 3-cyano-5alpha-androst-1-en-17-one; II, the 17beta-acetate form of I; III, 17beta-hydroxy-5beta-cyano-androstan-3-one; IV, 6-methylpregnenolone; V, 17beta-hydroxy-17alpha-ethynyl-5beta-cyano-19-norandrostan-3-one; and VI, 19-norspiroxenone (oestr-4-en-3-one-spiro-17alpha-2'-[tetrahydrofuran]) have been tested. After 6 weeks of treatment with daily doses of 5 mg (I, II, III), 15 mg (IV) or 10 mg (V, VI) only steroid VI blocked the completion of spermatogenesis and reduced the number of foetuses sired in at least five females/male. Steroid VI also diminished seminal vesicular, prostatic, testicular and epididymal weights. It inhibited the testicular enzymes, 3beta-hydroxysteroid dehydrogenase-delta4-5-3-oxosteroid isomerase system, 17alpha-hydroxylase, and C17-20 lyase markedly, but did not affect the adrenal dehydrogenase-isomerase system. It depressed, strikingly, testicular and serum levels of testosterone and 5alpha-dihydrotestosterone and reduced pituitary and serum levels of FSH and LH. Although marked depression of target organ weights also occurred with steroids II, IV and V, and reduction of androgen levels and LH in the circulation with III, IV and V, only VI was a potent blocker of male fertility with the exception of a slight block of the siring of viable foetuses by steroids IV and V. The major difference in site of action of steroid VI from the others was the depression of pituitary and serum levels of FSH along with a marked diminution of testicular content of both testosterone and 5alpha-dihydrotestosterone. 19-Norspiroxenone in the rat is a potent anti-oestrogen without inherent oestrogenicity and is anti-uterotrophic. Thus, VI may affect male fertility by virtue of its potent anti-oestrogenic action in the hypothalamus or testis.
D000731:Androstanes / Q000494:pharmacology; D000818:Animals; D003272:Contraceptive Agents, Male / Q000494:pharmacology*; D013196:Dihydrotestosterone / Q000378:metabolism; D004822:Epididymis / Q000187:drug effects; D004963:Estrenes / Q000494:pharmacology; D005298:Fertility / Q000187:drug effects*; D005640:Follicle Stimulating Hormone / Q000097:blood; D005663:Furans / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006913:Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008861:Microsomes / Q000187:drug effects; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D010902:Pituitary Gland / Q000032:analysis; D011278:Pregnanes / Q000494:pharmacology; D011467:Prostate / Q000187:drug effects; D051381:Rats; D012669:Seminal Vesicles / Q000187:drug effects; D013091:Spermatogenesis / Q000187:drug effects; D013251:Steroid Isomerases / Q000037:antagonists & inhibitors; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000378:metabolism
D000731:Androstanes; D003272:Contraceptive Agents, Male; D004963:Estrenes; D005663:Furans; D006727:Hormone Antagonists; D011278:Pregnanes; D013196:Dihydrotestosterone; D013739:Testosterone; C011318:19-norspiroxenone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D006899:Mixed Function Oxygenases; D006913:Hydroxysteroid Dehydrogenases; D013251:Steroid Isomerases